Through real-world observation, understanding clinical efficacy and safety of treatment with YISAIPU (etanercept biosimilar) for RA patients of Fujian Province for three years

This is a multi-center, prospective, real-world observational study. Patients who have completed 6 months of induction therapy (YISAIPU 50mg / week ± csDMARDs) and achieved clinical remission or low disease activity will be observed for 2.5 years. During the maintenance period, through full communication between doctors and patients, YISAIPU 50 mg/wk or YISAIPU 25 mg/wk will be chosen as maintenance treatment. The clinical efficacy evaluation parameters include DAS28, HAQ-DI, modified Sharp score, continuous medication rate, and the recurrence rate of rheumatoid arthritis. Drug safety evaluation will include the incidence of adverse drug reactions and adverse drug events, the incidence of serious adverse events, and the incidence of adverse events leading to the reduction or withdrawal of YISAIPU due to adverse events. Exploratory observations wil include: (1) the incidence, clinical characteristics and disease changes of Interstitial Lung Disease, (2) the baseline abnormal rate and 3-year change of carotid intima-media thickness.

Inclusion Criteria:

Inclusion criteria:

• Meet the ACR revised RA classification criteria(2010);
• Disease duration is more than or equal to 6 weeks;
• DAS28-CRP>2.6;
• Patient is eligible for TNF inhibitors treatment according to the judgment of the attending doctor in clinical practice;
• A written informed consent form must be provided with a signed and signed date prior to the commencement of any study specific procedure.

Exclusion Criteria:

Exclusion criteria:

• Patient has contraindication(s) to the use of fusion-protein type of TNF inhibitor;
• Patient is participating in other ongoing drug clinical trials;
• Patient whose LTBI screening result is positive, or had not received standard anti-TB treatment for TB history, is unwilling to take prophylactic treatment for TB;
• Patient with HBV infection and positive for HBV replication (not up to active replication) is not willing to receive anti-HBV treatment;
• Anti-HCV antibody is positive and HCV-RNA is positive, and patient is unwilling to start anti-HCV treatment;
• Other reasons the researchers think the patient is not eligible for participation in the study.

RA patients in routine clinical practice environments

share the study protocol

until completed

Scholars in rheumatism